



Atty.  
Dkt. No.

956707-5001-01

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit. 1645

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 1 of 1

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
UH	aa 3,837,340	09/1974	COUNTER			
	ab 3,948,263	04/1976	DRAKE			
	ac 3,982,536	09/1976	KROGSENG			
	ad 4,196,191	04/1980	ALMEIDA			
	ae 4,220,584	09/1980	LIMJUCO			
	af 4,235,871	11/1980	PAPAHADJOPOULOS			
	ag 4,285,931	08/1981	LIMJUCO			
	ah 4,394,448	07/1983	SZOKA			
	ai 4,411,888	10/1983	KLIPSTEIN			
	aj 4,455,142	06/1984	MARTINS			
	ak 4,484,923	11/1984	AMKRAUT			
	al 4,497,796	02/1985	SALSER			
	am 4,587,044	05/1988	MILLER			
	an 4,692,462	09/1987	BANERJEE			
	ao 4,725,271	02/1988	KOROL			
	ap 4,732,892	03/1988	SARPOTDAR			
	aq 4,743,588	05/1988	MIREJOVSKY			
	ar 4,761,372	08/1988	MAAS			
	as 4,764,381	08/1988	BODOR			
	at 4,783,450	11/1988	FAWZI			
	au 4,834,985	05/1989	ELGER			
	av 4,876,278	10/1989	TAYLOR			
	aw 4,877,612	10/1989	BERGER			
	ax 4,892,737	01/1990	BODOR			
	ay 4,908,389	03/1990	MAHJOUR			
UH	az 4,917,688	04/1990	NELSON			

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

OTHER INFORMATION: This order and the enclosed Name Patent Pages, etc.

Examiner: *gjs* Date Considered: 1/2/06  
\*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

056707-5001-01

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.

Appin. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit 1645

Page 2 of 14

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
CK	ba 4,917,895	04/1990	LEE			
	bb 4,921,757	05/1990	WHEATLEY			
	bc 4,929,442	05/1990	POWELL			
	bd 4,946,853	08/1990	BANNON			
	be 4,958,171	09/1990	CHANG			
	bf 4,960,771	10/1990	RAJADHYAKSHA			
	bg 4,970,208	11/1990	ALEXANDER			
	bh 5,008,050	04/1991	CULLIS			
	bi 5,008,111	04/1991	BODOR			
	bj 5,023,252	06/1991	HSIEH			
	bk 5,028,435	07/1991	KATZ			
	bl 5,030,629	07/1991	RAJADHYAKSHA			
	bm 5,032,402	07/1991	DIGENIS			
	bh 5,041,439	08/1991	KASTING			
	bo 5,045,317	09/1991	CHESS			
	bp 5,049,386	09/1991	EPPSTEIN			
	bq 5,049,387	09/1991	AMKRAUT			
	br 5,059,189	10/1991	CILENTO			
	bs 5,059,421	10/1991	LOUGHREY			
	bt 5,089,904	12/1991	MASTERSON			
	bu 5,082,868	01/1992	WONG			
	bv 5,108,921	04/1992	LOW			
	bw 5,142,044	08/1992	MINASKANIAN			
CK	bx 5,162,315	11/1992	RAJADHYAKSHA			
	by 5,164,406	11/1992	HELMAN			

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

--	--	--	--	--	--	--	--

Examiner: *[Signature]* Date Considered: 1/12/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

056707-5001-01

Applicants: **GLENN et al.**

**Appln. No. 10/790,715**

Filing Date: March 3, 2004

Examiner: Not Assigned	Group Art Unit 1645
------------------------	---------------------

Page 3 of 14

[illegible]

File:  dir:  inspire:  Author:  Title:  Name:  Page:  Pages:  Date:  User:

[illegible]

Examiner: [Signature] Date Considered: 7/2/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Applicants: GLENN et al.

**App'n. No.: 10/790,715**

**Filing Date:** March 3, 2004

Examiner: Not Assgn. Group Art Unit: 1645

## Page 4 of 14

[illegible]

Off: E-mail: phone: GMail: scribe: Author: Title: Periodical Name: Date: Penmen: Pages: etc.:

Examiner

Date Considered: 1/12/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PM&S FORM PAT-1449)  
Patent and Trademark Office

Atty.  
Dkt. No.

056707-5001-01

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.

Appl. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit 1645

Page 5 of 14

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
UP	ea 5,626,866	05/1997	EBERT			
	eb 5,643,578	07/1997	ROBINSON			
	ec 5,658,587	08/1997	SANTUS			
	ed 5,661,025	08/1997	SZOKA			
	ee 5,661,130	08/1997	MEEZAN			
	ef 5,674,503	10/1997	OLAFSON			
	eg 5,676,954	10/1997	BRIGHAM			
	eh 5,679,647	10/1997	CARSON			
	ei 5,686,100	11/1997	WILLE			
	ej 5,693,024	12/1997	FLOWER			
	ek 5,693,622	12/1997	WOLFF			
	el 5,695,991	12/1997	LINDHOLM			
	em 5,697,901	12/1997	ERIKSSON			
	en 5,698,416	12/1997	WOLF			
	ep 5,703,057	12/1997	JOHNSTON			
	ep 5,705,151	01/1998	DOW			
	eq 5,718,914	02/1998	FOLDVARI			
	er 5,720,948	02/1998	BRUCKS			
	es 5,722,397	03/1998	EPPSTEIN			
	et 5,723,114	03/1998	THORNFELDT			
	eu 5,731,303	03/1998	HSIEH			
	ev 5,733,572	03/1998	UNGER			
	ew 5,733,762	03/1998	MIDOUX			
	ex 5,736,154	04/1998	FUISZ			
UK	ey 5,736,392	04/1998	HAWLEY-NELSON			
	ez 5,736,524	04/1998	CONTENT			

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						No	Enclose
						No	No


Examiner

Date Considered: 1/12/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

**Applicants: GLENN et al.**

Appln. No. · 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned	Group Art Unit: 1645
------------------------	----------------------

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 6 of

## U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
UX	fa	5,738,647	04/1998	BERNHARD			
	fb	5,739,118	04/1998	CARRANO			
	fc	5,741,510	04/1998	ROLF			
	fd	5,756,117	05/1998	D'ANGELO			
	fe	5,760,096	06/1998	THORNFELDT			
	ff	5,766,899	08/1998	KUO			
	fg	5,770,580	06/1998	LEDLEY			
	fh	5,773,022	08/1998	NYQVIST-MAYER			
	fi	5,780,050	07/1998	JAIN			
	fj	5,783,567	07/1998	HEDLEY			
	fk	5,789,230	08/1998	COTTON			
	fl	5,804,214	09/1998	WONG			
	fm	5,804,566	09/1998	CARSON			
	fn	5,811,406	09/1998	SZOKA			
	fo	5,814,599	09/1998	MITRAGOTRI			
	fp	5,814,617	09/1998	HOFFMAN			
	fq	5,824,538	10/1998	BRANSTROM			
	fr	5,827,703	10/1998	DEBS			
	fs	5,827,705	10/1998	DEAN			
	ft	5,830,876	11/1998	WEINER			
	fu	5,830,877	11/1998	CARSON			
	fv	5,834,010	11/1998	QUAN			
	fw	5,837,289	11/1998	GRASELA			
	fx	5,837,533	11/1998	BOUTIN			
	fy	5,840,059	11/1998	MARCH			
UX	fz	5,843,913	12/1998	LI			

FOR PATIENT DOCUMENTS

[illegible]

Other: ☐ Uncertain ☐ Historic ☐ Author ☐ Title ☐ Periodical ☐ Name ☐ Date ☐ Remnant ☐ Pages, etc.

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Atty.  
Dkt. No.

056707-5001-01

Applicants: GLENN et al.

Appin. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assign. Group Art Unit 1645

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Page 7 of 14

U.S. PATENT DOCUMENTS						
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class Filing Date (if appropriate)
UK	ga	5,844,107	12/1998	HANSON		
	gb	5,846,540	12/1998	RESTIFO		
	gc	5,846,949	12/1998	WAGNER		
	gd	5,849,719	12/1998	CARSON		
	ge	5,853,751	12/1998	MASIZ		
	gf	5,856,187	01/1999	RESTIFO		
	gg	5,858,784	01/1999	DEBS		
	gh	5,868,553	02/1999	DONNELLY		
	gi	5,877,159	03/1999	POWELL		
	gj	5,877,302	03/1999	HANSON		
	gk	5,885,971	03/1999	GERMAN		
	gl	5,910,306	06/1999	ALVING		
	gm	5,910,488	06/1999	NABEL		
	gn	5,914,114	06/1999	CASSELS		
	go	5,916,879	06/1999	WEBSTER		
	gp	5,935,838	08/1999	ASKELOEF		
	gq	5,961,979	10/1999	SRIVASTAVA		
	gr	5,980,898	11/1999	GLENN		
	gs	5,985,847	11/1999	CARSON		
	gt	6,008,200	12/1999	KRIEG		
	gu	6,039,969	03/2000	TOMAI		
	gv	6,087,341	07/2000	KHAVARI		
	gw	6,173,202	01/2001	EPPSTEIN		
	gx	6,180,136	01/2001	LARSON		
UK	gy	6,183,434	02/2001	EPPSTEIN		
	gz	6,210,672	04/2001	COWING		

FOREIGN PATENT DOCUMENTS								English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Enclosed	No	Enclose	No

OTHER INFORMATION (Include name of State, Author, Title, Periodical Name, Date, Reprint, Page, etc.)											

Examiner: *[Signature]* Date Considered: *1/14/06*  
 \*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

## Applicants: GLENN et al.

Appln. No. 10/790,715

**Filing Date:** March 3, 2004

Examiner: Not Assigned	Group Art Unit 1645
------------------------	---------------------

Page 8 of 14

FOREIGN PATENT DOCUMENTS	English Abstract	Translation Readily
--------------------------	------------------	---------------------

[illegible]

Examiner

**Date Considered:**

30185091v1



056707-5001-01

**Applicants: GLENN et al.**

Appln. No. 10/790,715

**Filing Date:** March 3, 2004

Examiner: Not Assigned	Group Art Unit: 1645
------------------------	----------------------

Page 9 of 10

## U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS									
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (If appropriate)			
FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass			
							Enclosed	No	Enclose
							No		No

[illegible]

CP	ia	ALLISON "Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding" Arch Biochem Biophys 365 (1999) 289-298
	ib	ALLISON "Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran" J Pharm Sci 89 (2000) 199-214
	ic	ANDYA "The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody" Pharm Res 16 (1999) 350-358
	id	ARAKAWA "Protein-solvent interactions in pharmaceutical formulations" Pharma Res 8 (1991) 285-291
	ie	ARANY "Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (imiquimod) in genital warts" Antimicrob Agents Chemother 44 (2000) 1869-1873
	if	ALVING "Effectiveness of liposomes as potential carriers of vaccines: Applications to cholera toxin and human malaria sporozoite antigen" Vaccine 4 (1986) 168-172
	ig	ALVING "Liposomes as carriers of antigens and adjuvants" J Immunol Methods 140 (1991) 1-13
	ih	ALVING "Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants" Immunobiology 187 (1993) 430-448
	ii	ALVING "Novel adjuvant strategies for experimental malaria and AIDS vaccines" Ann NY Acad Sci 690 (1993) 265-275
	ij	ALVING "The preparation and use of liposomes in immunological studies" In: <i>Liposome Technology</i> , vol. 3, CRC Press (1993) pp. 317-343
	ik	ALVING "Cytotoxic T lymphocytes induced by liposomal antigens: Mechanisms of immunological presentation" AIDS Res Hum Retroviruses 10 suppl 2 (1994) S91-S94
	il	ALVING "Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides" Immunol Rev 145 (1995) 5-31
	im	BECKER "Mechanism in allergic contact dermatitis" Exp Dermatol 2 (1993) 63-69
	in	BIRCH "Trehaloses" Adv Carb Chem Biochem 18 (1963) 201-2225
	io	BLAUVELT "Human Langerhans cells express E-cadherin" J Invest Dermatol 104 (1995) 293-296
CP	ip	BOS "The 500 dalton rule for the skin penetration of chemical compounds and drugs" Exp Dermatol 9 (2000) 165-169

Examiner

**Date Considered:**

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

056707-5001-01

Applicants: GLENN et al.

Appin. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assig. Group Art Unit: 1645

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Page 10 of 14

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed No	Enclose No

OTHER (including articles, books, periodicals, newspapers, etc.)

ja	BOVSUN "DNA vaccine rubbed on skin provokes immune response" Biotechnol Newswatch (September 20, 1999) page 4
jb	BOWEN "Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens" Immunol 81 (1994) 338-342
jc	BUATES "Treatment of experimental Leishmaniasis with the immunomodulators Imiquimod and S-28463: Efficacy and mode of action" J Infect Dis 179 (1999) 1485-1494
jd	CHEN "induction of systemic immune responses in sheep by topical application of cholera toxin to skin" Vet Immunol Immunopathol 77 (2000) 191-199
je	CHIN "Antibody response against Pseudomonas aeruginosa membrane proteins in experimentally infected sheep" Vet Microbiol 43 (1995) 21-32
jf	CHIN "Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants" J Biotechnol 44 (1996) 13-19
yg	CONDON "DNA-based immunization by in vivo transfection of dendritic cells" Nature Med 2 (1996) 1122-1128
jh	COSTANTINO "Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone" J Pharm Sci 87 (1998) 1412-1420
ji	CRAIG "Cutaneous responses to cholera skin toxin in man. I. Responses in unimmunized American males" J Infect Dis 125 (1972) 203-215
jj	DE HAAN "Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice" Vaccine 13 (1995) 1320-1324
jk	EGBARIA "Liposomes as topical drug delivery system" Adv Drug Delivery Rev 5 (1990) 287-300
jl	ENK "An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin" J Immunol 151 (1993) 2390-2398
jm	FAN "Immunization via hair follicles by topical application of naked DNA to normal skin" Nature Biotechnol 17 (1999) 870-872
jn	FLEISHER "Topical delivery of growth hormone releasing peptide using liposomal systems: An in vitro study using hairless mouse skin" Life Sci 57 (1995) 1293-1297
jo	FRANK "Long-term stabilization of biologicals" Bio/Technology 12 (1994) 253-256

Examiner

Date Considered: 1/14/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

056707-5001-01

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit: 1645

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Page 11 Of 14

Domestic Patent Documents							Class		Sub Class		Filing Date (if appropriate)	
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)									
Foreign Patent Documents												
	Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract		Translation Readily Available			
							Enclosed	No	Enclose	No		
OTHER PUBLICATIONS: Direct Author, Title, Periodical Name, Date, Periodical Page, etc.												
UK	ka			GEKKO "Mechanism of protein stabilization by glycerol: Preferential hydration in glycerol-water mixtures" Biochemistry 20 (1981) 4667-4676								
	kb			GLENN "Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A" Immunol Lett 47 (1995) 73-78								
	kc			GLENN "Skin immunization made possible by cholera toxin" Nature 391 (1998) 851								
	kd			GLENN "Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge" J Immunol 161 (1998) 3211-3214								
	ke			GLENN "Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants" Infect Immun 67 (1999) 1100-1106								
	kf			GLENN "Transcutaneous immunisation" Exp Opin Invest Drugs 8 (1999) 797-805								
	kg			GLENN "Transcutaneous immunization" In: The Jordan Report 2000, NIAID, pp. 91-93								
	kh			GLENN "Transcutaneous immunization: A human vaccine delivery strategy using a patch" Nature Med 6 (2000) 1403-1406								
	ki			GLENN "Transcutaneous immunization" In: Vaccine Adjuvants, Humana Press (April 2000) pp. 315-326								
	kj			GLENN "Transcutaneous immunization" In: New Vaccine Technologies, Landes Biosciences (June 2001) pp. 292-304								
	kk			GOODNOW "Chance encounters and organized rendezvous" Immunol Rev 156 (1997) 5-10								
	kl			GUPTA "Adjuvants for human vaccines - current status, problems and future prospects" Vaccine 13 (1995) 1263-1276								
	km			HAMMOND "Transcutaneous immunization of domestic animals: Opportunities and challenges" Adv Drug Delivery Rev 43 (2000) 45-55								
	kn			HAMMOND "Transcutaneous immunization: T cell responses and boosting of existing immunity" Vaccine 19 (2001) 2701-2707								
	ko			HANSON "Introduction to formulation of protein pharmaceuticals" In: Stability of Protein Pharmaceuticals, Plenum (1992) pp. 209-233								
UK	kp			HOELZLE "Increased accumulation of trehalose in rhizobia cultured under 1% oxygen" Appl Environ Microbiol 56 (1990) 3213-3215								

Examiner

Date Considered: 11/12/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

056707-5001-01

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assgn. Group Art Unit 1645

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Page 12 Of 14

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

Initials	Number	Date	Country	Inventor Name	Class	SubClass	English Abstract		Translation Readily Available	
FOREIGN PATENT DOCUMENTS							Enclosed	No	Enclose	No
	Document Number	Date MM/YYYY								

OTHER INFORMATION ON THIS FORM: Author, Title, Inventor Name, Patent Number, Page, Date

1a	HSIUNG <i>Diagnostic Virology 3<sup>rd</sup> Ed.</i> , Yale Univ. Press (1982) pp. 29-34
1b	IIZUKA "Two simple methods for the evaluation of topically active anti-inflammatory steroidal ointments" <i>Agents Actions</i> 11 (1981) 254-259
1c	IZUTSU "Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices" <i>Pharm. Res</i> 12 (1995) 838-843
1d	JOHNSON "Vaccination onto bare skin" <i>Nature</i> 388 (1997) 729-730
1e	KAHAN "Immunosuppressive therapy" <i>Current Opin Immunol</i> 4 (1992) 553-560
1f	KNOP "Cellular and molecular mechanisms in the induction phase of contact sensitivity" <i>Intl Arch Allergy Immunol</i> 107 (1995) 231-232
1g	KORTING "Topical liposome drugs to come: what the patent literature tells us" <i>J Am Acad Dermatol</i> 25 (1991) 1068-1071
1h	KORTING "Interaction of liposomes with human epidermis reconstructed in vitro" <i>Br J Dermatol</i> 132 (1995) 571-579
1i	KOSECKA "Pertussis toxin stimulates hypersensitivity and enhances nerve-mediated antigen uptake in rat intestines" <i>Am J Physiol</i> 267 (1994) G745-G752
1j	LANE "In vitro-evaluation of human lymphocyte function" In: <i>Handbook of Experimental Immunology 4<sup>th</sup> Ed.</i> , vol. 2, Blackwell (1988) pp. 66.5-66.7
1k	LUO "Synthetic DNA delivery systems" <i>Nature Biotechnol</i> 18 (2000) 33-37
1l	MAHMOUD "Parasitic protozoa and helminths: Biological and immunological challenges" <i>Science</i> 246 (1989) 1015-1022
1m	MARINARO "Mucosal effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4" <i>J Immunol</i> 155 (1995) 4621-4629
1n	MENGIARDI "Virosomes as carriers for combined vaccines" <i>Vaccine</i> 13 (1995) 1306-1315
1o	MEZEI "Liposomes - a selective drug delivery system for the topical route of administration. Lotion dosage form" <i>Life Sci</i> 26 (1980) 1473-1477
1p	MOGHIMI "Current progress and future prospects of liposomes in dermal drug delivery" <i>J Microencapsul</i> 10 (1993) 155-162
1q	NORIMATSU "Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine" <i>Vaccine</i> 13 (1995) 1325-1329

Examiner

Date Considered: 7/1/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Applicants: GLENN et al.**

Appln. No. 10/790,715

**Filing Date:** March 3, 2004

Examiner: Not Assigned	Group Art Unit: 1645
------------------------	----------------------

Page 13 of 14

## PATENT REQUIREMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
----------------------	-----------------	--------------	--------------------------------------	-------	-----------	------------------------------

## FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Abstract		Recovery Available	
								Enclosed	No	Enclose	No

ATTENTION: In order to authorize Herodias Name, Date, Penner, Pages, etc.

ma	PAUL "Transdermal immunization with large proteins by means of ultradeformable drug carriers" Eur J Immunol 25 (1995) 3521-3524
mb	PAUL "Noninvasive administration of protein antigens: Transdermal immunization with bovine serum albumin in transferosomes" Vaccine Res 4 (1995) 145-164
mc	PETERS "Dendritic cells: From ontogenetic orphans to myelo-monocytic descendants" Immunol Today 17 (1996) 273-278
md	POWERS "In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant" Vaccine 13 (1995) 1330-1335
me	RANADE "Drug delivery systems. 6. Transdermal drug delivery" J Clin Pharmacol 31 (1991) 401-418
mf	RAO "Intracellular processing of liposome-encapsulated antigens by macrophages depends upon the antigen" Infect Immun 63 (1995) 2396-2402
mg	SANCHEZ "Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres" Int J Pharm 185 (1999) 255-266
mh	SAUZET "Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides" Vaccine 13 (1995) 1339-1345
mi	SCHAEFER-KORTING "Liposome preparations: A step forward in topical drug therapy for skin disease?" J Am Acad Dermatol 21 (1989) 1271-1275
mj	SCHARTON-KERSTEN "Principles of transcutaneous immunization using cholera toxin as an adjuvant" Vaccine 17 suppl 2 (1999) S37-S43
mk	SCHARTON-KERSTEN "Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants" Infect Immun 68 (2000) 5308-5313
ml	SCHMITT "Bacterial toxins: Friends or foes" Emerging Infect Dis 5 (1999) 224-234
mm	SCHWARZENBERGER "Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ" J Invest Dermatol 106 (1996) 553-558
mn	SEO "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis" Proc Natl Acad Sci USA 97 (2000) 371-376
mo	SMALL, In: <i>Handbook of Lipid Research</i> , Plenum, 4:43-87 and 89-96
mp	STACEY "Macrophages ingest and are activated by bacterial DNA" J Immunol 157 (1996) 2116-2122

**Examiner**

**Date Considered:**

Examiner \_\_\_\_\_ Date Considered: \_\_\_\_\_

\*EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Atty.  
Dkt. No.

056707-5001-01

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit 1645

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Page 14 of 14

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

FOREIGN PATENT DOCUMENTS							English Abstract	Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass			
							Enclosed	No	Enclose No

na	STEINMAN "Dendritic cells in the T-cell areas of lymphoid organs" Immunol Rev 156 (1997) 25-37
nb	STINGL "The immune functions of epidermal cells" Immunol Ser 48 (1989) 3-72
nc	SUZUKI "Imiquimod, a topical immune response modifier, induces migration of Langerhans cells" J Invest Dermatol 114 (2000) 135-141
nd	UDEY "Cadherins and Langerhans cell immunobiology" Clin Exp Immunol 107 suppl 1 (1997) 6-8
ne	VASSELL "Activation of Langerhans cells following transcutaneous immunization" 13 FASEB J (1999) A633
nf	VERMA "Phagocytosis of liposomes by macrophages: intracellular fate of liposomal malaria antigen" Biochim Biophys Acta 1066 (1991) 229-238
ng	VERMA "Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages" Infect Immun 60 (1992) 2438-2444
nh	VUTLA "Transdermal iontophoretic delivery of enkephalin formulated in liposomes" J Pharm Sci 85 (1996) 5-8
ni	WALKER "The role of percutaneous penetration enhancers" Adv Drug Delivery Rev 18 (1996) 295-301
nj	WANG "Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine" J Immunol 154 (1995) 2784-2793
nk	WANG "Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice" J Immunol 156 (1996) 4077-4082
nl	WASSEF "Liposomes as carriers for vaccines" Immunomethods 4 (1994) 217-222
nm	WEINER "Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model" Antimicrob Agents Chemotherap 33 (1989) 1217-1221
nn	WHITE "Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes" Vaccine 11 (1993) 1341-1346
no	WHITE "Antibody and cytotoxic T-lymphocyte responses to a single liposome associated peptide antigen" Vaccine 13 (1995) 1111-1122
np	YASUTOMI "A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge" J Virol 69 (1995) 2279-2284
nq	ZELLMER "Interaction of phosphatidylcholine liposomes with the human stratum corneum" Biochim Biophys Acta 1237 (1995) 176-182

Examiner

Date Considered: 1/12/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if no in conformance and not considered. Include copy of this form with next communication to Applicant.



<b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
(Use several sheets if necessary)				Applicants: Gregory M Glenn <i>et al.</i>		Page 15 of 19	
PTO Form 1449				Filing Date: March 3, 2004		Group Art Unit: 1645	

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
YK	Y1	3,964,482	06/1976	GERSTEL			
	Y2	4,775,361	10/1988	JACQUES			
	Y3	4,810,499	03/1989	NUWAYSER			
	Y4	5,003,987	04/1991	GRINWALD			
	Y5	5,133,970	07/1992	PETEREIT			
	Y6	5,182,109 C1	10/2001	TAMURA			
	Y7	5,250,023	10/1993	LEE			
	Y8	5,279,544	01/1994	GROSS			
	Y9	5,688,523	11/1997	GARBE			
	Y10	5,879,326	03/1999	GODSHALL			
	Y11	5,885,211	03/1999	EPPSTEIN			
	Y12	5,993,849	11/1999	ASSMUS			
	Y13	5,993,852	11/1999	FOLDVARI			
	Y14	6,019,982	02/2000	CLEMENTS			
	Y15	6,022,316	02/2000	EPPSTEIN			
	Y16	6,033,673	03/2000	CLEMENTS			
	Y17	6,033,684	03/2000	NORCIA			
	Y18	6,063,399	05/2000	ASSMUS			
	Y19	6,090,790	07/2000	ERIKSSON			
	Y20	6,142,939	11/2000	EPPSTEIN			
	Y21	6,149,919	11/2000	DOMENIGHINI			
	Y22	6,165,458	12/2000	FOLDVARI			
	Y23	6,165,500	12/2000	CEVC			
	Y24	6,190,367	02/2001	HALL			
	Y25	6,190,689	02/2001	HOFFMAN			
	Y26	6,207,184	03/2001	IKEDA			
	Y27	6,256,533	07/2001	YUZHAKOV			
UK	Y28	6,290,991	09/2001	ROSER			
	Y29	6,312,612	11/2001	SHERMAN			

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes No

OTHER DOCUMENTS		

Examiner:	Date Considered: 1/12/06
-----------	--------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
(Use several sheets if necessary)				Applicants: Gregory M Glenn <i>et al.</i> Page 16 of 19			
PTO Form 1449				Filing Date: March 3, 2004		Group Art Unit: 1645	

U.S. PATENT DOCUMENTS							
*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date	
UPK	Y30	6,331,266	12/2001	POWELL			
	Y31	6,331,310	12/2001	ROSER			
	Y32	6,334,856	01/2002	ALLEN			
	Y33	6,348,212	02/2002	HYMES			
	Y34	6,348,450	02/2002	TANG			
	Y35	6,365,178	04/2002	VENKATESHWARAN			
	Y36	6,379,324	04/2002	GARTSTEIN			
	Y37	6,406,705	06/2002	DAVIS			
	Y38	6,413,523	07/2002	CLEMENTS			
	Y39	6,440,096	08/2002	LASTOVICH			
	Y40	6,451,240	09/2002	SHERMAN			
	Y41	6,454,755	09/2002	GODSHALL			
Y42	6,471,903	10/2002	SHERMAN				

FOREIGN PATENT DOCUMENTS							
Document Number	Date	Country	Class	Sub Class	Translation Yes No		
UPK	Y43	WO 95/17211	06/1995	WIPO			
	Y44	WO 96/06627	03/1996	WIPO			
	Y45	WO 96/19976	04/1996	WIPO			
	Y46	WO 96/37256	11/1996	WIPO			
	Y47	WO 97/04832	02/1997	WIPO			
	Y48	WO 97/07734	03/1997	WIPO			
	Y49	WO 98/00193	01/1998	WIPO			
	Y50	WO 98/29134	07/1998	WIPO			
	Y51	WO 99/13915	03/1999	WIPO			
	Y52	WO 99/26662	06/1999	WIPO			
	Y53	WO 99/47164	09/1999	WIPO			
	Y54	WO 99/47165	09/1999	WIPO			
Y55	WO 99/47167	09/1999	WIPO				
Y56	WO 99/61078	12/1999	WIPO				
Y57	WO 00/33812	06/2000	WIPO				
Y58	WO 00/74714	12/2000	WIPO				

OTHER DOCUMENTS	
Examiner:	Date Considered: 1/24/06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
(Use several sheets if necessary)				Applicants: Gregory M Glenn <i>et al.</i> <span style="float: right;">Page 17 of 19</span>			
PTO Form 1449				Filing Date: March 3, 2004		Group Art Unit: 1645	

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes No
CJL	Y59	WO 00/74763	12/2000	WIPO			
	Y60	WO 00/74763 A3	12/2000	WIPO			
	Y61	WO 00/74766	12/2000	WIPO			
	Y62	WO 01/34185	05/2001	WIPO			
	Y63	WO 01/90758	11/2001	WIPO			
	Y64	WO 02/02179	01/2002	WIPO			
	Y65	WO 02/05889	01/2002	WIPO			
	Y66	WO 02/07813	01/2002	WIPO			
	Y67	WO 02/64162	08/2002	WIPO			
	Y68	WO 02/64193	08/2002	WIPO			
CJL	Y69	WO 02/74244	09/2002	WIPO			


  

OTHER DOCUMENTS		
CJL	Y70	BECKER "Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs) - A novel approach to the protection of human" Virus Genes 9 (1994) 33-45
	Y71	BECKER "An analysis of the role of skin Langerhans cells (LC) in the cytoplasmic processing of HIV-1 peptides after "peplotion" transepidermal transfer and HLA class I presentation to CD8+ CTLs - An approach to immunization of humans" Virus Genes 9 (1995) 133-147
	Y72	CASTLE "Clinical relevance of age-related immune dysfunction" Clin Infect Dis 31 (2000) 578-585
	Y73	CHEN "Adjuvation of epidermal powder immunization" Vaccine 19 (2001) 2908-2917
	Y74	CHEN "Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization" J Virol 75 (2001) 7956-7965
	Y75	EL-GHORR "Transcutaneous immunization with herpes simplex virus stimulates immunity in mice" FEMS Immunol Med Microbiol 29 (2000) 255-61
CJL	Y76	FENG "P55, an immunogenic but nonprotective 55-kilodalton Borrelia burgdorferi protein in murine Lyme disease" Infect Immun 64 (1996) 363-365

Examiner:	Date Considered: 1/12/06
-----------	--------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
(Use several sheets if necessary)  PTO Form 1449				Applicants: Gregory M Glenn <i>et al.</i>			
				Filing Date: March 3, 2004		Page 18 of 19 Group Art Unit: 1645	
<b>U.S. PATENT DOCUMENTS</b>							
<b>*Examiner Initial</b>		<b>Document Number</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date</b>
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Sub Class</b>	<b>Translation Yes No</b>
<b>OTHER DOCUMENTS</b>							
YK	Y77	GLUECK "Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine <i>Escherichia coli</i> heat-labile toxin as a mucosal adjuvant" J Infect Dis 181 (2000) 1129-1132					
	Y78	GOCKEL "Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract" Mol Immunol 37 (2000) 537-544					
	Y79	HAGIWAR "Effectiveness and safety of mutant <i>Escherichia coli</i> heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine" Vaccine 19 (2001) 2071-2079					
	Y80	HAGIWARA "Effects of intranasal administration of cholera toxin (or <i>Escherichia coli</i> heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain" 19 Vaccine (2001) 1652-1660					
	Y81	HIOE "Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides" Vaccine 14 (1996) 412-418					
	Y82	JANEWAY Immunobiology (1994) 10:78-10:79					
	Y83	KALBITZ "Modulation der wirkstoffpenetration in die haut" Pharmazie 51 (1996) 619-637					
	Y84	KATOH "Acute cutaneous barrier perturbation induces maturation of Langerhans' cells in hairless mice" Acta Derm Venereol 77(1997) 65-69					
	Y85	KUMAMOTO "Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine" Nat Biotechnol 20 (2002) 64-69					
	Y86	LIU "Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses" Vaccine 20 (2001) 42-48					
	Y87	LU "Mutant <i>Escherichia coli</i> heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine" Vaccine 20 (2002) 1019-1029					
YK	Y88	MURPHY "Antigen-Induced Protective and Nonprotective Cell-Mediated Immune Components against <i>Cryptococcus neoformans</i> " Infect Immun 66 (1998) 2632-2639					
Examiner: 				Date Considered: 2/12/06			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
(Use several sheets if necessary)				Applicants: Gregory M Glenn <i>et al</i> <span style="float: right;">Page 19 of 19</span>			
PTO Form 1449				Filing Date: March 3, 2004		Group Art Unit: 1645	

U.S. PATENT DOCUMENTS							
*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date	
CK	Y89	5,910,306	08/1999	Glenn			
CK	Y90	5,980,898	11/1999	Glenn			
CK	Y91	6,797,276	02/1999	Glenn			

FOREIGN PATENT DOCUMENTS							
Document Number	Date	Country	Class	Sub Class	Translation Yes No		

OTHER DOCUMENTS		
Y92	CK	OCKENHOUSE "Sequestrin, a CD36 recognition protein on <i>Plasmodium falciparum</i> malaria-infected erythrocytes identified by anti-idiotypic antibodies" Proc Natl Acad Sci 88 (1991) 3175-3179
Y93		OGRA "Vaccination strategies for mucosal immune responses" Clin Microbiol Rev 14 (2001) 430-445
Y94		PODDA "The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine" Vaccine 19 (2001) 2673-2680
Y95		WILLIAMS "Skin absorption enhancers" Critical Rev in Therapeutic Drug Carrier Systems 9 (1992) 305-353
Y96		TAKIGAWA "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis" Ann N Y Acad Sci 941 (2001) 139-146
Y97		TANG "Vaccination onto bare skin" Nature 388 (1997) 729-730
Y98		"Tuberculin, Purified protein Derivative, Tine Test" Physician's desk Reference, 3 pages (2001)
Y99	CK	WATABE "Protection against influenza virus challenge by topical application of influenza DNA vaccine" Vaccine 14 (2001) 4434-4444

Examiner:	Date Considered:
-----------	------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.